Johnson & Johnson

| July 27, 2016

The Olympic Games are fast approaching, and Brazil will soon host the world’s best athletes, along with thousands of fans. But the conversation dominating the headlines surrounding the Summer Games is not who will go for the gold. It’s the mosquito-borne virus known as Zika....

| July 27, 2016

Dramatic changes in healthcare are happening all around us. And through these changes, companies like Johnson & Johnson have a remarkable opportunity to transform lives for the better. We have a vision for the future that is rooted in fully leveraging technology. We believe the intersection of technology and healthcare is spurring innovation that will have a profound impact on patients and consumers globally....

Johnson & Johnson | July 26, 2016

RARITAN, NJ – July 26, 2016 -- Janssen Biotech, Inc. announced today it has entered into a clinical study collaboration agreement with Bristol-Myers Squibb Company to evaluate the combination of two immuno-oncology compounds in patients with non-small cell lung cancer (NSCLC). The Phase 2 clinical trial will evaluate the tolerability and clinical activity of the combination of Janssen’s investigational immunotherapy JNJ-64041757 and Bristol-Myer Squibb’s PD-1 immune checkpoint inhibitor, OPDIV...

Johnson & Johnson | July 18, 2016

TITUSVILLE, NJ, July 18, 2016 – Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion to the PREZISTA® (darunavir) U.S. Prescribing Information to include data and results from a study investigating the use of PREZISTA® during pregnancy and the postpartum period....